KIT and neutropenia: Hence, in this study, the drug‐to‐antibody ratio (DAR) of NN2101‐DM1 was optimized to be below 2 to minimize c‐Kit‐mediated on‐target adverse effects, including neutropenia and hematopoietic stem cell depletion [37, 38, 42].